Medmira (47M) AI Stock Analysis

Medmira

(Frankfurt:47M)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue ReboundThe TTM revenue rebound indicates materially stronger product demand and market activity. If sustained, higher sales can improve operating leverage and support scale across healthcare and public-health customers, although profitability conversion remains unproven.

Negative Factors

Persistent UnprofitabilityDeeply negative gross margin and continuing operating and net losses show that revenue growth has not yet translated into viable unit economics. Without sustained gross-profit improvement, future scale could increase losses rather than create durable earnings.

Medmira (47M) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 35.09M
Dividend Yield: ―
Average Volume (3M): 5,725
Price to Earnings (P/E): -11.4
Beta (1Y): 0.01
Revenue Growth: 36.43%
EPS Growth: 38.64%
Country: Germany
Employees: 52
Sector: General
Sector Strength: 55
Industry: Biotechnology

Medmira Business Overview & Revenue Model

Company Description

MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific regi...

Medmira Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:47M against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:COV	70Outperform	CAD 122.35M	28.16	15.04%	―	4.11%	88.39%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:MBX	52Neutral	CAD 41.09M	-8.50	-18.83%	―	-27.13%	-1752.63%
TSE:DTC	43Neutral	CAD 26.53M	-3.17	-424.91%	―	―	-54.70%
TSE:SVA	41Neutral	CAD 39.65M	-3.57	57.10%	―	―	48.06%
TSE:NRX	33Underperform	CAD 37.32M	-4.51	-337.24%	―	―	19.02%

* General Sector Average

Performance Comparison

DE:47M and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:47M	Medmira Inc	0.02	-0.02	-46.34%
TSE:COV	Covalon Technologies	4.43	2.33	110.95%
TSE:MBX	Microbix Biosystms	0.30	0.04	15.38%
TSE:SVA	Sernova Corp	0.10	-0.04	-30.00%
TSE:NRX	Nurexone Biologic Inc.	0.48	-0.21	-30.43%
TSE:DTC	Defence Therapeutics Inc	0.35	-0.45	-56.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medmira AI Stock Analysis